
Our state-of-the-art facility has been highlighted in the renowned Pharma Outlook Book, a testament to our growing presence and recognition in the international pharmaceutical landscape. This feature underscores our dedication to innovation, compliance, and delivering high-quality pharmaceutical solutions.

We are delighted to announce our participation in CPhI Worldwide, Milan, Italy (06-08 October 2026), showcasing our capabilities at the heart of global pharma innovation.

Our pivotal bioequivalence (BE) studies are now available for advanced formulations, including:
Duloxetine HCL EC Pellets 17%
Venlafaxine HCL SR Pellets 33%